WO2005042742A1 - サルnpy y4受容体及び化合物の評価方法 - Google Patents
サルnpy y4受容体及び化合物の評価方法 Download PDFInfo
- Publication number
- WO2005042742A1 WO2005042742A1 PCT/JP2004/016242 JP2004016242W WO2005042742A1 WO 2005042742 A1 WO2005042742 A1 WO 2005042742A1 JP 2004016242 W JP2004016242 W JP 2004016242W WO 2005042742 A1 WO2005042742 A1 WO 2005042742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- npy
- receptor
- seq
- protein
- monkey
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Definitions
- the present invention provides a novel monkey neuropeptide Y (hereinafter referred to as NPY) Y4 receptor gene, a protein, a recombinant vector containing the gene, and a transformed cell containing the recombinant vector. And a method for evaluating a compound using the gene or protein.
- NPY monkey neuropeptide Y
- NPY is a peptide having 36 amino acids and was isolated from pig brain by Tatsumoto et al. In 1982 (Non-Patent Document 1). NPY is widely distributed in the central nervous system and the peripheral nervous system, and as one of the most abundant peptides in the nervous system, controls various functions in vivo.
- NPY acts as an appetite-promoting substance in the center and remarkably promotes fat accumulation through secretion of various hormones or action of the nervous system.
- continuous intraventricular administration of NPY is known to induce obesity and insulin resistance based on these effects.
- NPY is also known to have central effects such as depression, anxiety, schizophrenia, pain, dementia and regulation of circadian rhythm.
- NPY coexists with norepinephrine in the peripheral sympathetic nerve endings and is associated with sympathetic tone.
- Peripheral administration of NPY is known to cause vasoconstriction and enhance the action of other vasoconstrictors, including norepinephrine.
- NPY is a receptor that is partially common to its analog Peptide-YY (hereinafter, referred to as PYY) and pancreatic polypeptide (hereinafter, referred to as PP).
- PYY Peptide-YY
- PP pancreatic polypeptide
- NPY and related peptides are expressed by binding to NPY receptors present in the central or peripheral nervous system. Therefore, inhibition of the binding of NPY and related peptides to the NPY receptor can prevent the expression of these pharmacological effects.
- substances that antagonize the binding of NPY and related peptides to NPY receptors include various diseases involving NPY and related peptides, such as angina pectoris, acute and congestive heart failure, myocardial infarction, hypertension, kidney disease, and electrolytes.
- Cardiovascular diseases such as abnormalities and vasospasm, such as bulimia, depression, anxiety, convulsions, epilepsy, dementia, pain, alcoholism, withdrawal symptoms associated with withdrawal of drugs, circadian rhythm modulation, and integration
- Nervous system diseases such as ataxia, memory disorders, sleep disorders, cognitive disorders, etc., for example, obesity, diabetes, hormonal abnormalities, gout, metabolic diseases such as fatty liver, infertility, premature birth, sexual dysfunction, etc. It is expected to be useful in the prevention or treatment of gastrointestinal diseases, respiratory diseases, inflammatory diseases or glaucoma. Recently, some NPs
- Y receptor antagonists have been found to be useful in the prevention or treatment of hypercholesterolemia, hyperlipidemia, and arteriosclerosis (Patent Document 1).
- NPY Y4 receptor a human NPY Y4 receptor gene has already been isolated as a gene-level analysis (Non-Patent Document 7, Non-Patent Document 8, Patent Document 2).
- the human NPY Y4 receptor was isolated by screening a human genomic library using the NPY Y1 receptor cDNA as a probe, has a seven-transmembrane structure, and differs from the Y1 receptor at the amino acid level.
- Patent Document 1 International Publication No. 99Z27965 pamphlet
- Patent Document 2 International Publication No.95Z17906 pamphlet
- Non-patent literature l Nature, vol. 296, p. 659 (1982)
- Non-Patent Document 2 Trends in Neuroscience, Volume 20, Page 294 (1997)
- Non-Patent Document 3 Gastroenterology, 85, 1411 (1983)
- Non-Patent Document 4 Endocrinology ⁇ 140, 5171 (1999)
- Non-Patent Document 5 Gastroenterology ⁇ 124, 1325 (2003)
- Non-Patent Document 6 The Journal of Clinical Endocrinology & Metabolism ⁇ 8
- Non-Patent Document 7 The Journal of Biological Chemistry, Vol. 270, 26762 (1995)
- Non-Patent Document 8 The Journal of Biological Chemistry, Vol. 270, p. 29123 (1995)
- NPY Y4 receptor gene of non-human primates has not yet been isolated, and it has not been possible to evaluate therapeutic or diagnostic agents using such genes. .
- the present invention has been made in view of the above-mentioned problems of the prior art, and has as its object to provide NPY Y4 receptor genes and proteins of primates other than humans. Means for solving the problem, which is to provide a method for evaluating a compound using the gene or protein
- the present inventors succeeded in isolating the Y4 receptor gene, and also succeeded in evaluating a ligand by a binding experiment using the receptor. Thus, the present invention was completed.
- nucleic acid of the present invention is characterized by including the nucleotide sequence of SEQ ID NO: 1 or 3.
- the nucleic acid of the present invention is also characterized in that it has the nucleotide sequence of SEQ ID NO: 1 or 3.
- a monkey NPY Y4 receptor gene (a monkey-derived gene encoding a protein having an activity as an NPY Y4 receptor) comprising such a nucleic acid is also provided by the present invention.
- nucleic acid of the present invention is characterized by encoding the protein having the amino acid sequence described in SEQ ID NO: 2 or 4.
- a monkey NPY Y4 receptor gene that also has such a nucleic acid power is provided by the present invention.
- nucleic acid of the present invention hybridizes under stringent conditions to a nucleic acid consisting of the nucleotide sequence of SEQ ID NO: 1 or 3 or a nucleotide sequence complementary thereto, and has an activity as an NPY Y4 receptor. Characterized in that it is an isolated nucleic acid derived from a monkey, which encodes a protein having the same. A monkey NPY Y4 receptor gene comprising such a nucleic acid is also provided by the present invention.
- a recombinant vector of the present invention is characterized by containing the above-described nucleic acid or gene. Further, the transformed cell of the present invention is characterized by containing the recombinant vector.
- the protein of the present invention is characterized by including the amino acid sequence of SEQ ID NO: 2 or 4.
- the protein of the present invention is characterized by comprising the amino acid sequence of SEQ ID NO: 2 or 4.
- the protein of the present invention comprises an amino acid sequence represented by SEQ ID NO: 2 or 4 in which one or more amino acids have been substituted, deleted, added or inserted, and has an N PY Y4 receptor. It is an isolated protein having an activity as a body.
- nucleic acid By using such a nucleic acid, gene, protein, recombinant vector or transformed cell, it becomes possible to construct an expression system for a primate (mainly monkey) NPY Y4 receptor or a mutant thereof. At the same time, it becomes possible to construct a system for evaluating a conjugate using the expression system.
- a primate mainly monkey
- NPY Y4 receptor or a mutant thereof.
- a system for evaluating a conjugate using the expression system By using such a nucleic acid, gene, protein, recombinant vector or transformed cell, it becomes possible to construct an expression system for a primate (mainly monkey) NPY Y4 receptor or a mutant thereof. At the same time, it becomes possible to construct a system for evaluating a conjugate using the expression system.
- the method for evaluating a compound of the present invention comprises the steps of: introducing a monkey NPY Y4 receptor gene to prepare a cell that expresses the receptor; and contacting the cell with a test compound. Detecting the specific binding of the test compound to the receptor. It is characterized by the following.
- the method for evaluating a compound of the present invention comprises the steps of: introducing a monkey NPY Y4 receptor gene and preparing a cell that expresses the receptor; and bringing a test compound into contact with the cell. Measuring the activity of the intracellular signaling substance produced by the contact, and comparing the activity with the activity of the intracellular signaling substance when the test compound is not brought into contact with the cell. It is characterized by.
- the method for evaluating a compound of the present invention comprises the steps of: contacting a test compound with a monkey NPY Y4 receptor protein (a monkey-derived protein having activity as an NPY Y4 receptor); Detecting a change in the activity of the protein by the method described above.
- a monkey NPY Y4 receptor protein a monkey-derived protein having activity as an NPY Y4 receptor
- nucleic acids, proteins and compounds of the present invention it is possible to obtain NPYY4 receptor genes and proteins of non-human primates, and to obtain compounds using the genes or proteins. Evaluation and screening can be performed. Therefore, it is possible to evaluate and develop therapeutic and diagnostic agents using the gene or protein.
- FIG. 1 is a graph showing the relationship between the membrane fraction concentration and the amount of human PP bound when the nucleic acid of the present invention (SEQ ID NO: 1) is used.
- FIG. 2 is a graph showing the relationship between the concentration of the membrane fraction and the amount of human PP bound when the nucleic acid of the present invention (SEQ ID NO: 3) is used.
- FIG. 3 is a graph showing the relationship between the peptide concentration of human PP, human NPY and porcine PYY and the amount of human PP bound when using the nucleic acid of the present invention (SEQ ID NO: 1).
- FIG. 4 is a graph showing the relationship between the peptide concentration of human PP, human NPY and porcine PYY and the amount of human PP bound when the nucleic acid of the present invention (SEQ ID NO: 3) is used.
- FIG. 5 is a graph showing the relationship between the concentration of human PP and the change in fluorescence intensity in cells transfected with the nucleic acid of the present invention (SEQ ID NO: 1 or 3).
- nucleic acid in the present invention refers to, for example, DNA, RNA, or modified DNA or RNA, and preferably DNA.
- the DNA may be single-stranded or double-stranded regardless of whether it is genomic DNA or cDNA.
- isolated nucleic acid or protein in the present invention refers to a nucleic acid or a protein that is substantially free of cell material and culture medium when produced by recombinant DNA technology and chemically synthesized. Refers to nucleic acids or proteins that are substantially free of precursor or other substances.
- to hybridize under stringent conditions refers to the power of two nucleic acid fragments: Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Novel (1989), 9.47 -9.62 and 11.45-11.61 [This means that the two hybridize under the noidization conditions described above. More specifically, for example, a condition in which hybridization is performed at 6.0 X SSC at about 45 ° C, followed by washing with 2.0xSSC at 50 ° C.
- the salt concentration in the washing step can range, for example, from about 2.OxSSC, 50 ° C for low stringency to about 0.2 ⁇ SSC, 50 ° C for high stringency. You can choose.
- the temperature of the washing step can be increased from room temperature, about 22 ° C under low stringency conditions, to about 65 ° C under high stringency conditions.
- rhesus monkey NPY Y4 receptor genes there are two types whose nucleotide sequences are clear (SEQ ID NOS: 1 and 3), which differ by one base. Each of these genes has an open reading frame of 1128 bases and encodes a 375 amino acid protein (SEQ ID NOs: 2 and 4). However, the base at position 1111 in the translation region is different, and the amino acid at position 361 is different based on this difference. The present inventors believe that the strong difference is due to genetic polymorphism. [0032] The method of closing the rhesus monkey NPY Y4 receptor gene is not particularly limited.
- the rhesus monkey NPY Y4 receptor gene or a nucleic acid fragment derived from the gene having high homology to the gene is used.
- These methods can be performed by methods well known to those skilled in the art, for example, see Proc. Natl. Acad. Sci. USA, vol. 85, p. 8998 (1988).
- the homology between the rhesus monkey NPY Y4 receptor gene shown in SEQ ID NO: 1 and the human NPY Y4 receptor gene is about 95.6% in the coding region. And differ by 50 bases.
- the homology between the rhesus monkey NPY Y4 receptor gene shown in SEQ ID NO: 3 and the human NPY Y4 receptor gene is 95.5% in the coding region, and differs by 51 bases.
- the nucleic acids of the present invention also include those having substitution, deletion, insertion or addition of one or more bases in the base sequence of SEQ ID NO: 1 or 3, preferably 1-49 bases, More preferably, there may be substitution, deletion, insertion or addition of 110 bases, further preferably 110 bases, particularly preferably 110 bases, and still more preferably 115 bases. Further, based on the homology, the nucleotide sequence of the nucleic acid having the substitution, deletion, insertion or addition preferably has a homology of 96% or more with the nucleotide sequence of SEQ ID NO: 1 or 3. It is more preferably at least 97%, more preferably at least 98%, particularly preferably at least 99%.
- the nucleic acid having the substitution, deletion, insertion or addition is synthesized under stringent conditions with the nucleotide sequence described in SEQ ID NO: 1 or 3 or a nucleotide sequence complementary thereto.
- the nucleic acid can be obtained by isolating a nucleic acid to be hybridized, and the type thereof is not particularly limited as long as it is a biologically active nucleic acid.
- the NPY Y4 receptor gene derived from monkeys is preferably a monkey-derived NPY Y4 receptor gene, for example, a rhesus monkey, a power monkey, a Japanese macaque, a squirrel monkey, a green monkey, NPY Y4 receptor gene of Anubis baboon or common marmoset.
- the present invention also includes a protein having the amino acid sequence of SEQ ID NO: 2 or 4, or a mutant thereof.
- a protein having the amino acid sequence of SEQ ID NO: 2 or 4 has 375 amino acids as described above. The amino acid at position 361 is different between these two proteins.
- Examples of the mutant include a protein comprising an amino acid sequence in which 1 or 2 or more and 16 or less amino acids are substituted, deleted or inserted in the amino acid sequence of SEQ ID NO: 2 or 4, or 1 or 2 or more
- a protein comprising an amino acid sequence to which an amino acid is added may be mentioned.
- Such muteins more preferably have NPY Y4 receptor activity, which is preferably biologically active.
- the method for preparing the rhesus monkey NPY Y4 receptor protein is not particularly limited, but specifically, for example, after inserting the isolated rhesus monkey NPY Y4 receptor gene into the expression vector, A recombinant vector) into an animal cell, an insect cell, or a host cell such as Escherichia coli to express the gene, and purify the gene product protein.
- the brute force method can be performed by a method well known to those skilled in the art, for example, referring to Molecular Cloning: A Laboratory Manual, 2nd edition, 3rd edition, Cold Spring Harbor (1989, 2001). it can.
- the present invention also provides an expression vector (recombinant vector) containing any of the following nucleic acids or genes.
- An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or 3.
- An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or a monkey NPY Y4 receptor gene comprising the nucleic acid.
- An isolated nucleic acid encoding a protein having the amino acid sequence described in SEQ ID NO: 2 or 4, or a monkey NPY Y4 receptor gene comprising the nucleic acid.
- a monkey which hybridizes under stringent conditions to a nucleic acid having the nucleotide sequence of SEQ ID NO: 1 or 3 or a nucleotide sequence complementary thereto and encodes a protein having an activity as an NPY Y4 receptor
- An isolated nucleic acid derived therefrom, or a sal NPY Y4 receptor gene which also has this nucleic acid capacity.
- the recombinant vector of the present invention can be obtained by inserting the nucleic acid or gene of the present invention into an appropriate expression vector according to a known method.
- the expression vector and There are no particular restrictions on vectors known to those skilled in the art.For example, pcDNA3.1, pBlueBacHis2, pCI-neo, pcDNAI, pMClneo, pXTl, pSG5, pEFl / V5-HisB, pCR2.1, pETl l or gtl l.
- the recombinant vector of the present invention is capable of autonomous replication in host cells and, at the same time, contains a promoter, a ribosome binding sequence (SD sequence) and a terminator.
- SD sequence ribosome binding sequence
- the term "comprising the nucleotide sequence of SEQ ID NO: 1 or 3" in the above 1. means that the above-mentioned base sequence contains a linker sequence with a vector or a restriction enzyme cleavage site usable for gene recombination. A sequence necessary for modification of a gene such as a position is added.
- the present invention also provides a host cell (transformed cell) containing the recombinant vector.
- the transformed cell of the present invention can be obtained by introducing the recombinant vector of the present invention into an appropriate host cell according to a known method.
- the host cell may be any of animal cells, insect cells, plant cells, and microorganisms, as long as they are well known to those skilled in the art.
- the viable cells include, for example, COSl, COS 7, CHO, NIH / 3T3, 293, Raji, CV11, C1271, MRC-5, CPAE, L-M (TK-I), HeLa or Sf9 Is mentioned.
- the method for introducing the recombinant vector into a host cell is not particularly limited as long as it is a known method.
- Specific examples include, for example, an electoporation method, a calcium phosphate method, a DEAE-dextran method, a lipofection method or a gene. Gun method.
- the present invention also includes an antibody against a protein having the amino acid sequence of SEQ ID NO: 2 or 4, or a mutant thereof.
- the antibody can be prepared using the protein or a partial peptide thereof as an antigen, and may be a monoclonal antibody or a polyclonal antibody.
- the antibody may react not only with the monkey NPY Y4 receptor protein but also with a heterologous NPY Y4 receptor protein depending on the amino acid sequence serving as the epitope, but the antibody has selectivity only for the monkey NPY Y4 receptor protein
- a monoclonal antibody is prepared using a region of the monkey NPY Y4 receptor protein having low homology with a heterologous NPY Y4 receptor protein as a peptide antigen.
- Antibodies with specificity can be prepared.
- the uses of the nucleic acid having the base sequence of SEQ ID NO: 1 or 3 and the protein having the amino acid sequence of SEQ ID NO: 2 or 4 according to the present invention will be listed and described.
- the compound acting on the NPY Y4 receptor can be evaluated using the nucleic acid or protein of the present invention.
- Methods for detecting the presence or absence or the extent of the action on the NPY Y4 receptor include a method for detecting specific binding of a test compound to the receptor, a method for detecting the expression level of a gene altered by contact with a test compound, And a method for detecting the activity of intracellular signal transduction via the NPY Y4 receptor generated by the contact.
- the method for evaluating a compound of the present invention comprises the steps of: introducing a monkey NPY Y4 receptor gene and preparing a cell that expresses the receptor; contacting the cell with a test compound; Detecting the specific binding of the test compound to the test compound.
- the second method for evaluating a compound of the present invention comprises the steps of: introducing a monkey NPY Y4 receptor gene to prepare a cell that expresses the receptor; and bringing a test compound into contact with the cell.
- test compound is not particularly limited, and examples thereof include proteins, peptides, non-peptide conjugates, and artificially synthesized conjugates.
- nucleic acid having the nucleotide sequence of SEQ ID NO: 1 or 3 of the present invention or a nucleic acid capable of partially acting on the nucleic acid is cloned into an expression vector containing a suitable promoter and transcription control element.
- the vector is not particularly limited as long as it can be used as an expression vector.
- an expression vector (recombinant vector) into which the nucleic acid or gene of the present invention has been inserted is introduced into host cells.
- the powerful host cell is not particularly limited as long as it is normally used for gene expression, and may be any of animal cells, insect cells, plant cells, and microorganisms. Specifically, for example, COSl , COS7, CHO, NIH / 3T3, 293, Raji, CVI I, C1271, MRC-5, CPAE, LM (TK-), HeLa or Sf9.
- the method for introducing the recombinant vector into a host cell is not particularly limited as long as it is a known method.
- Specific examples include, for example, electoporation, calcium phosphate method, DEAE-dextran method, lipofection method or The gene gun method is mentioned.
- the test compound is brought into contact with the cells (transformed cells) expressing the NPY Y4 receptor thus prepared.
- the contacting method is not particularly limited, and examples thereof include a method of contacting in a solution such as an aqueous solution or a buffer solution.
- the binding between the receptor expressed on the cell surface and the test compound can be determined, for example, by detecting with a label attached to the bound compound (for example, detecting the amount of binding by radioactivity or fluorescence intensity), or by measuring the cell membrane. Examples include methods based on binding experiments using fractions, which can be performed by methods known to those skilled in the art.
- signal transduction into cells by binding of the test compound to the receptor on the cell surface for example, activation of G protein, change in Ca 2+ or cAMP concentration (FLI PR (Fluorometric Imaging Plate Reader), etc.) ), Phospholipase C activation, and pH change.
- the expression level or activity of a molecule on a signal transduction pathway generated by the signal transduction can be used as an index.
- the method for measuring the expression level is not particularly limited, and examples include Northern blotting, real-time PCR, and a DNA chip.
- a method for measuring the activity is not particularly limited, and a suitable method may be selected depending on the type of the molecule to be measured.
- the isolated monkey NPY Y4 receptor protein can be directly used for compound evaluation. That is, a test compound is brought into contact with the monkey NPY Y4 receptor, and then a change in the activity of the protein caused by the contact is detected.
- a test compound is brought into contact with the monkey NPY Y4 receptor, and then a change in the activity of the protein caused by the contact is detected.
- the method is not particularly limited. Specifically, for example, a method of contacting by mixing in a solution such as a buffer solution (phosphate buffer solution or the like), or a method in which the protein is immobilized on a membrane and A method of contacting with a test compound is exemplified.
- a method for detecting a change in the activity of a protein may be appropriately determined depending on the properties of the protein to be used. Specifically, for example, a method using the binding activity of NPY and related peptides to NPY Y4 receptor as an index Is mentioned.
- the method for using the binding activity of NPY and related peptides as an index is not particularly limited. Specifically, for example, the affinity of a test compound for a membrane on which an NPY Y4 receptor protein is immobilized is determined. There is a method of measuring the binding activity by measuring.
- the test compound used here may be labeled with a radioisotope or the like for easy detection.
- a method for detecting the binding activity there is also a method of detecting a compound that binds to the NPY Y4 receptor by competing with NPY labeled with a radioisotope and a related peptide. Does not require labeling of the test compound
- the binding activity of NPY and related peptide in the presence of the test compound the binding activity of NPY and related peptide in the absence of the test compound (
- the test compound shows a lower ⁇ ⁇ value than that of the control, it is determined that the test compound inhibits the binding between the NPY Y4 receptor and the ligand or its analog.
- Such compounds include compounds having an activity of inducing signal transduction into cells by binding to the receptor (agonist) and compounds having no such activity (antagost), etc. .
- the agonist has the same physiological activity as the ligand for the receptor.
- Antagonists do not have the physiological activity of the ligand for the receptor and inhibit the binding of the ligand to the receptor. Therefore, these agonists and antagonists are useful as pharmaceutical compositions for treating diseases caused by abnormalities in the signal transduction system via the NPY Y4 receptor.
- the method for evaluating a compound of the present invention allows screening for a substance that promotes or inhibits the activity of NPY Y4 receptor. That is, by the method described above, By evaluating the number of test compounds, a compound that functions as an agonist or an antagonist can be selected. As a result of such selection, if the change in the cells is suppressed as compared with the change in the cells when the ligand or its analog is acted in the absence of the test compound, the test compound will be NPY Y4 It is determined that the compound inhibits the activity of the receptor.
- the compound is determined to be a compound that promotes the activity of the NPY Y4 receptor according to the present invention.
- the conjugates selected by such a screening method can be used for various diseases involving NPY, such as angina pectoris, acute and congestive heart failure, myocardial infarction, hypertension, kidney disease, electrolyte abnormalities, and vasospasm.
- Organ disorders such as binge eating, depression, anxiety, convulsions, epilepsy, dementia, pain, alcoholism, withdrawal from drug withdrawal, circadian rhythm modulation, schizophrenia, memory impairment, sleep disorders, Nervous system diseases such as cognitive disorders, e.g., obesity, diabetes, abnormal hormonal secretion, gout, metabolic diseases such as fatty liver, infertility, premature birth, sexual dysfunction, etc. It is considered useful for the prevention or treatment of diseases, inflammatory diseases, hypercholesterolemia, hyperlipidemia, arteriosclerosis or glaucoma.
- the ligand for use in positron emission tomography can be evaluated by the above-described method for evaluating the compound of the present invention.
- PET with water, oxygen, glucose and amino acids! / This is a non-invasive method for observing biological functions by labeling radioactive substances and drugs (such as ligands for target receptors) existing in the body with a radioactive substance. Used in clinical practice.
- the feature of PET is that it enables function-specific imaging depending on the ligand used as a tracer, and the development of a new tracer is indispensable for elucidating unknown biological functions and diagnosing diseases.
- the compound evaluation method of the present invention by applying a PET ligand candidate substance as a test compound, it becomes possible to evaluate the substance at the in-vivo mouth.
- the NPY Y4 receptor gene can be detected by using a part or all of the nucleic acid of the nucleotide sequence set forth in SEQ ID NO: 1 or 3 of the present invention as a probe for hybridization. It is possible. For powerful detection, test tissues and cells from living organisms The present invention can be applied not only to detection of the NPY Y4 receptor gene but also to closing of the ⁇ 4 receptor gene or a gene highly homologous to the gene. In addition, the distribution of gene expression can be identified by examining gene expression in various tissues using the nucleic acid as a probe.
- the hybridization method is not particularly limited. For example, Southern hybridization, Northern hybridization, and colony hybridization Chillon, dot hybridization, fluorescence in situ hybridization (FISH) ⁇ in situ hybridization (ISH) ⁇ DNA chip method.
- FISH fluorescence in situ hybridization
- ISH in situ hybridization
- the nucleic acid When the nucleic acid is used as a probe for hybridization, it is necessary to have a continuous nucleic acid having a length of at least 20 bases, preferably 40 bases, more preferably 60 bases, and particularly preferably 60 bases. Preferably 80 bases or more are used.
- the probe may be labeled and used so that it can be detected as necessary. Specifically, for example, it is labeled with a radioactive isotope such as 32 P, 14 c, 125 ⁇ , 3 H, and 35 S, and is labeled with a biotin, a fluorescent dye, an enzyme, a gold colloid, or the like.
- a radioactive isotope such as 32 P, 14 c, 125 ⁇ , 3 H, and 35 S
- hybridization conditions are determined according to the length of the probe and the type of the gene to be hybridized.
- a person skilled in the art may appropriately select, for example, see Molecular C oning: A Laboratory Manual, 2nd edition, Cold Spring Harbor (1989), 9.47-9.62 and 11.45-11.61. It can be carried out. More specifically, the conditions for carrying out the hybridization with about 45 Q G [trowel 6.0 X SSC], then washing with 50 o G [trowel 2. OxSSC] are mentioned.
- the salt concentration in the washing step may be adjusted to, for example, about 2.OxSSC at 50 ° C for low stringency, about 0.2 ⁇ SSC at 50 ° C for high stringency, 50 ° C You can choose up to. Further, the temperature of the washing step can be increased from low stringency conditions at room temperature, about 22 ° C, to high stringency conditions at about 65 ° C.
- PCR Polymerase Chain Reaction
- the length of such a primer can be appropriately set depending on its nucleotide sequence, the nucleotide sequence of the gene to be isolated, and the like. Generally, it is preferable that the length be 10 to 60 consecutive nucleotides. More preferably, it is 15-30 bases.
- Oligo DNA primers were designed. Using the genus DNA of cynomolgus monkey (Clontech) as type III, these primers were used to repeat the cycle of 94 ° C for 10 seconds (denaturation reaction), Z55 ° C for 1 minute (annealing) and Z68 ° C for 2 minutes (extension reaction) 40 times. A PCR reaction was performed.
- the obtained PCR amplification product was digested with restriction enzymes BamHI and Notl, and cloned into pEFl / V5-HisB plasmid vector (Invitrogen).
- Six clones were randomly selected from the clones obtained from six independent PCR reactions.
- the nucleotide sequence was determined by the dye terminator method using 7-16). By comparing the nucleotide sequences of these six clones, the nucleotide sequences of the two rhesus monkey ⁇ 4 receptor genes of SEQ ID NOS: 1 and 3 became clear.
- Both SEQ ID NOs: 1 and 3 have an open reading frame of 1128 bases (30th to 1157th).
- the amino acid sequences (375 residues) predicted from each open reading frame are shown in SEQ ID NOs: 2 and 4.
- hY4-4FBamHI ATCGGATCCG TCATCCCTCA AGTGTATCAC TTAGTTC (SEQ ID NO: 5)
- hY4-1323RNotI CATGCGGCCG CAAACAGCTC TTGCCAGCCT ATCTGG (SEQ ID NO: 6)
- T7 TAATACGACT CACTATAGGG (SEQ ID NO: 7)
- Y42 GCTGTTGAAC ACATGCAGAG (SEQ ID NO: 10)
- Y48 TTATGCACGC ATCTACCGGC (SEQ ID NO: 16).
- Example 2 Expression of rhesus monkey Y4 receptor by COS-7 cells and binding to [ 12 human]
- COS-7 cells (American Type Culture Collection) were seeded at a density of 5 ⁇ 10 4 cells in a 24-well culture plate, and after 24 hours, the nucleotide sequences of SEQ ID NOS: 1 and 3 obtained in Example 1 were retained.
- the PEF1ZV5-HisB plasmid vector and the same vector without insert (mock) were transfected using Efectene (Qiagen).
- a reaction buffer of 240 1 / well mixed with 50 pM [ 125 1] human PP (PerkinElmer) (Hanks containing 20 mM HEPES, 0.2% serum albumin, balanced salt) The mixture was incubated at 37 ° C for 30 minutes in a solution, pH 7.4). After washing with ice-cold reaction buffer, cells were lysed and recovered with 2M NaOH, and a ⁇ counter (Packa Radioactivity was measured by Cobra, Inc. (rd company).
- the amount of non-specific binding was measured by adding 1 ⁇ m of human to the above reaction solution.
- the PEF1ZV5-HisB plasmid vector carrying the sequences of SEQ ID NOS: 1 and 3 was transfected into COS-7 cells using LipofectAmine Plus (Invitrogen). After 48 hours, the cells were collected and placed in a lOmM MOPS buffer (pH 7.4) containing 20% sucrose, 154 mM NaCl, 10 mM KC1 and 0.8 mM CaCl while cooling on ice with a Polytron homogenizer.
- the membrane fraction concentration was set to 0.155 and 0.14 mg protein Zml
- human PP concentration was set to 59 pM
- various concentrations of human PP, human NPY and porcine PYY were added to the above reaction solution.
- IC value 50% inhibitory concentration was determined using Prism Version 4.00 (GraphPad) from the specific [ 12 3 ⁇ 4 human PP binding inhibition curves ( Figures 3 and 4).
- the protein that is loaded has a higher affinity for PP than NPY or PYY !, a known Y4 receptor [The Journal Biological Chemistry, 270, 26762 (1995); The Journal Biological Chemistry, 270 ⁇ , 29123M (1995 ⁇ ); FEBS Letters, 381, 58 (1996); Proceedings of the National Academy of Sciences of the United States of America, 93, 4661 (1995;); Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, p. 5111 (1995)].
- Example 4 CHO-K1 cells co-expressing rhesus monkey Y4 receptor and Go; protein
- nucleic acids, proteins and compounds of the present invention it is possible to obtain NPYY4 receptor genes and proteins of non-human primates, and to obtain compounds using the genes or proteins. Evaluation and screening can be performed. Therefore, it becomes possible to evaluate and develop a therapeutic or diagnostic agent using the gene or protein. Therefore, it greatly contributes to the efficiency of research and development of human medicine.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/577,826 US20070083037A1 (en) | 2003-10-30 | 2004-11-01 | Monkey npy y4 receptor and method of evaluating compound |
JP2005515200A JPWO2005042742A1 (ja) | 2003-10-30 | 2004-11-01 | サルnpyy4受容体及び化合物の評価方法 |
EP04799448A EP1688494A4 (en) | 2003-10-30 | 2004-11-01 | MONKEY NPY Y4 RECEPTOR AND METHOD FOR ASSESSING A CONNECTION |
CA002543999A CA2543999A1 (en) | 2003-10-30 | 2004-11-01 | Monkey npy y4 receptor and method of evaluating compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003369840 | 2003-10-30 | ||
JP2003-369840 | 2003-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005042742A1 true WO2005042742A1 (ja) | 2005-05-12 |
Family
ID=34543836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016242 WO2005042742A1 (ja) | 2003-10-30 | 2004-11-01 | サルnpy y4受容体及び化合物の評価方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20070083037A1 (ja) |
EP (1) | EP1688494A4 (ja) |
JP (1) | JPWO2005042742A1 (ja) |
CA (1) | CA2543999A1 (ja) |
WO (1) | WO2005042742A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017906A1 (en) * | 1993-12-28 | 1995-07-06 | Synaptic Pharmaceutical Corporation | Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053864A1 (en) * | 2000-01-20 | 2004-03-18 | Gerard Karsenty | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
-
2004
- 2004-11-01 EP EP04799448A patent/EP1688494A4/en not_active Withdrawn
- 2004-11-01 CA CA002543999A patent/CA2543999A1/en not_active Abandoned
- 2004-11-01 JP JP2005515200A patent/JPWO2005042742A1/ja active Pending
- 2004-11-01 US US10/577,826 patent/US20070083037A1/en not_active Abandoned
- 2004-11-01 WO PCT/JP2004/016242 patent/WO2005042742A1/ja not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995017906A1 (en) * | 1993-12-28 | 1995-07-06 | Synaptic Pharmaceutical Corporation | Dna encoding a human neuropeptide y/peptide yy/pancreatic polypeptide receptor (y4) and uses thereof |
Non-Patent Citations (2)
Title |
---|
BARD A. ET AL.: "Cloning and Functional Expression of a Human Y4 Subtype Receptor for Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, 1995, pages 26762 - 26765, XP002187958 * |
See also references of EP1688494A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1688494A1 (en) | 2006-08-09 |
CA2543999A1 (en) | 2005-05-12 |
JPWO2005042742A1 (ja) | 2008-02-21 |
EP1688494A4 (en) | 2007-08-08 |
US20070083037A1 (en) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008154594A (ja) | ヒトgタンパク質共役レセプターの内因性バージョンおよび非内因性バージョン | |
JP2004526441A (ja) | 内因性および非内因性型ヒトgタンパク質共役受容体 | |
JP2000083669A (ja) | Cxcr4ケモカイン受容体のヒトスプライス変異体cxcr4b | |
JPH11169187A (ja) | 新規化合物 | |
JP2001525178A (ja) | ヒト11cbスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法 | |
JP2002505872A (ja) | 7回膜貫通gタンパク質共役受容体ecr673 | |
US6998239B1 (en) | Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine | |
US7108990B2 (en) | Chemokine receptor | |
WO2005042742A1 (ja) | サルnpy y4受容体及び化合物の評価方法 | |
WO2001027146A9 (en) | Chemokine receptor | |
WO2005121356A1 (ja) | 新規スクリーニング方法 | |
US7696339B2 (en) | Nucleic acid encoding monkey QRFP | |
KR100971270B1 (ko) | 이피에프 수용체 에세이, 화합물 및 치료학적 조성물 | |
KR20010113052A (ko) | 신규한 5-ht4 수용체의 클로닝 및 발현 | |
WO2000058462A1 (fr) | Nouvelles proteines de recepteur couplees aux proteines de liaison a la guanosine triphosphate (gtp), bg3 | |
JP2002512016A (ja) | Edgファミリー遺伝子、ヒトh218 | |
WO2000031107A1 (en) | 7tm receptor hlwar77 | |
JP2002522044A (ja) | 7tm受容体(gpr31a)の分子クローニング | |
USRE39849E1 (en) | Methods for identifying modulators of CCX CKR activity | |
JPWO2005045042A1 (ja) | サルorl1遺伝子及び化合物の評価方法 | |
JP2004500864A (ja) | 新規g−タンパク質共役型受容体 | |
JPWO2003087364A1 (ja) | 新規g蛋白質共役型受容体及びその遺伝子 | |
JP2004503241A (ja) | 甲状腺刺激ホルモン放出ホルモン受容体様gpcr(gprfwki) | |
WO2003102147A2 (en) | Mutants of gad65 and ian5 relating to diabetes | |
TW201131168A (en) | Methods and compositions for identifying modulators of G protein-coupled receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005515200 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2543999 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004799448 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004799448 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007083037 Country of ref document: US Ref document number: 10577826 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10577826 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004799448 Country of ref document: EP |